OncoWuXi Express: Paclitaxel-Induced Resistant Tumor Models
Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as...
Continue Reading
Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as...
Continue Reading
Expanded Role of PDX Models in Anticancer Drug Development Patient-derived xenograft (PDX) models are established by implanting surgically resected patient...
Continue Reading
Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer...
Continue Reading
Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription...
Continue Reading
Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types. PKN3 mRNA is almost undetectable in normal adult...
Continue Reading
Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to...
Continue Reading
NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer...
Continue Reading
Rat tumor models are a better mimic of human pathology compared to mice. The tumor stroma component of rats is...
Continue Reading
The efficacy of CAR-T therapy is substantially influenced by the tumor microenvironment. This is particularly evident when PD-L1 is activated...
Continue Reading